GlassScriptPhysician profile
Melissa E Rezk
NPI 1114411477
$2,303.83
in general payments reported to CMS, 2019-2025
21 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $235 · 2022: $398 · 2023: $560 · 2024: $754 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,620 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,620.13 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $751.88 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $285.02 | 2021-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Lilly USA, LLC | $241.48 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Insulet Corporation | $202.53 | 2021-2025 | Omnipod |
| Dexcom, INC. | $154.26 | 2022-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $97.63 | 2021-2024 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $81.93 | 2023-2025 | Gvoke Hypopen |
| Kyowa Kirin, INC. | $76.26 | 2024-2025 | Crysvita |
| Beta Bionics, INC. | $75.71 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.56 | 2022-2024 | Jardiance |
| Horizon Therapeutics Plc | $40.33 | 2023 | Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $31.57 | 2021-2022 | |
| Antares Pharma, INC. | $29.48 | 2024 | Xyosted |
| Sequel Med Tech, LLC | $27.23 | 2025 | Twiist |
| Amgen INC. | $23.75 | 2024 | Tepezza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $23.73 | 2023 | Afrezza |
| Ardelyx, INC. | $21.21 | 2024 | Ibsrela |
| Alkermes, INC. | $20.96 | 2021 | |
| Amphastar Pharmaceuticals, INC. | $18.84 | 2025 | Baqsimi |
| Tandem Diabetes Care, INC. | $15.56 | 2022 | |
| Pfizer INC. | $11.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Rezk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.